Metformin and cancer occurrence in insulin-treated type 2 diabetic patients

Diabetes Care

Volumn 34, Issue 1, 2011, Pages 129-131

  Monami, Matteo ^a   Colombi, Claudia ^b   Balzi, Daniela ^c   Dicembrini, Ilaria ^a   Giannini, Stefano ^a   Melani, Cecilia ^c   Vitale, Valentina ^a   Romano, Desiderio ^a   Barchielli, Alessandro ^c   Marchionni, Niccolò ^b   Rotella, Carlo Maria ^a   Mannucci, Edoardo ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Careggi Teaching Hospital   (Italy)

^c Local Health Unit 10   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE PLUS METFORMIN; INSULIN; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; SEX DIFFERENCE;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; SULFONYLUREA COMPOUNDS;

EID: 79951708837     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1287     Document Type: Article

References (13)

1. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258 (Pubitemid 44106500)
2. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305 (Pubitemid 40813563)
3. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32: 1620-1625
4. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-1685
5. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297-3302
6. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009;69:6539-6545
7. Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002;25: 2133-2140 (Pubitemid 41071017)
8. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM: Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010;33:1997-2003
9. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47: 1245-1251 (Pubitemid 24361532)
10. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123
11. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273 (Pubitemid 44799743)
12. Grenader T, Goldberg A, Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol 2009;27:e259
13. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203